{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:02:24Z","timestamp":1779667344861,"version":"3.53.1"},"publisher-location":"Cham","reference-count":28,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032200402","type":"print"},{"value":"9783032200419","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-3-032-20041-9_3","type":"book-chapter","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T23:03:12Z","timestamp":1779663792000},"page":"41-54","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Target-Based Discovery of Drug Combinations for Spinal Muscular Atrophy"],"prefix":"10.1007","author":[{"given":"Rza","family":"Bashirov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"3_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/978-1-84996-474-6_8","volume-title":"Modeling in systems biology","author":"J Ackermann","year":"2011","unstructured":"Ackermann J, Koch I (2011) Quantitative analysis. In: Koch I, Reisig W, Schreiber F (eds) Modeling in systems biology. The petri nets approach. Springer, London, pp 153\u2013278"},{"key":"3_CR4","doi-asserted-by":"publisher","first-page":"104562","DOI":"10.1016\/j.biosystems.2021.104562","volume":"210","author":"\u0130N Ak\u00e7ay","year":"2021","unstructured":"Ak\u00e7ay \u0130N, Bashirov R (2021) Comparison of modelling approaches demonstrated for p16\u2013mediated signalling pathway in higher eukaryotes. BioSyst 210:104562","journal-title":"BioSyst"},{"key":"3_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2019.06.007","volume":"100","author":"SA Al-Zaidy","year":"2019","unstructured":"Al-Zaidy SA, Mendell JR (2019) From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1. Pediatr Neurol 100:3\u201311","journal-title":"Pediatr Neurol"},{"issue":"3","key":"3_CR10","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1172\/JCI29562","volume":"117","author":"AM Avila","year":"2007","unstructured":"Avila AM, Burnett BG, Taye AA, Gabanella F, Knight MA, Hartenstein P, Cizman Z, Di Prospero NA, Pellizzoni L, Fischbeck KH, Sumner CJ (2007) Trichostatin a increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest 117(3):659\u2013671","journal-title":"J Clin Invest"},{"key":"3_CR19","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40263-022-00941-1","volume":"36","author":"HA Blair","year":"2022","unstructured":"Blair HA (2022) Onasemnogene abeparvovec: a review in spinal muscular atrophy. CNS Drugs 36:995\u20131005","journal-title":"CNS Drugs"},{"issue":"19","key":"3_CR21","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1093\/hmg\/ddg256","volume":"12","author":"L Brichta","year":"2003","unstructured":"Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl FA, Raschke H, Blumcke I, Eyupoglu IY, Wirth B (2003) Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 12(19):2481\u20132489","journal-title":"Hum Mol Genet"},{"key":"3_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3233\/JND-230162","volume":"11","author":"N Cornell","year":"2024","unstructured":"Cornell N, Childs AM, Wraige E, Munot P, Ambegaonkar G, Chow G, Hughes I, Illingworth M, Majumdar A, Marini-Bettolo C, Parasuraman D (2024) Risdiplam in spinal muscular atrophy: safety profile and use through the early access to medicine scheme for the paediatric cohort in Great Britain. Neuromuscul Dis 11: 361\u2013368","journal-title":"Neuromuscul Dis"},{"issue":"2","key":"3_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S1090-3798(99)80012-9","volume":"3","author":"V Dubowitz","year":"1999","unstructured":"Dubowitz V (1999) Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype. Eur J Paediatr Neurol 3(2):49\u201351","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"3_CR32","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1747-0285.2009.00781.x","volume":"73","author":"D Dayangac-Erden","year":"2009","unstructured":"Dayangac-Erden D, Bora G, Ayhan P, Kocaefe C, Dalkara S et al (2009) Histone deacetylase inhibition activity and molecular docking of (E)-Resviratrol: its therapeutic potential in spinal muscular atrophy. Chem Biol Drug Des 73(3):355\u2013364","journal-title":"Chem Biol Drug Des"},{"key":"3_CR45","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.braindev.2014.10.006","volume":"37","author":"NI Harahap","year":"2015","unstructured":"Harahap NI, Takeuchi A, Yusoff S et al (2015) Trinucleotide insertion in the SMN2 promoter may not be related to the clinical phenotype of SMA. Brain Dev 37:669\u2013676","journal-title":"Brain Dev"},{"key":"3_CR47","doi-asserted-by":"crossref","unstructured":"Hastings ML, Berniac J, Liu YH, Abato P, Jodelka FM, Barthel L, Kumar S, Dudley C, Nelson M, Larson K et al (2009) Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for Spinal Muscular Atrophy. Sci Transl Med 1:5ra12","DOI":"10.1126\/scitranslmed.3000208"},{"key":"3_CR48","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/hmg\/ddn357","volume":"18","author":"J Hauke","year":"2009","unstructured":"Hauke J, Riessl M, Lunke S, Ey\u00fcpoglu IY, Bl\u00fcmcke I, El-Osta A, Wirth B, Hahnen E (2009) Survival motor neuron gene 2 silencing by DNA methylation correlates with Spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition. Hum Mol Genet 18:304\u2013317","journal-title":"Hum Mol Genet"},{"key":"3_CR50","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/978-3-642-31131-4_22","volume-title":"33rd international conference on application and theory of petri nets","author":"M Heiner","year":"2012","unstructured":"Heiner M, Herajy M, Liu F, Rohr C (2012) Snoopy a unifying Petri net tool. In: 33rd international conference on application and theory of petri nets, Hamburg, Germany, pp 398\u2013407"},{"issue":"1","key":"3_CR54","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/71709","volume":"24","author":"HM Hsieh-Li","year":"2000","unstructured":"Hsieh-Li HM, Chang JG, Jong YJ, Wu MH, Wang NM, Tsai CH, Li H (2000) A mouse model for spinal muscular atrophy. Nat Genet 24(1):66\u201370","journal-title":"Nat Genet"},{"key":"3_CR56","first-page":"2003","volume":"14","author":"J Jarecki","year":"2005","unstructured":"Jarecki J, Chen X, Bernardino A, Coovert DD, Whitney M, Burghes A, Stack J, Pollok BA (2005) Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for Spinal Muscular Atrophy Hum Mol Genet 14:2003\u20132018","journal-title":"Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for Spinal Muscular Atrophy Hum Mol Genet"},{"key":"3_CR61","doi-asserted-by":"publisher","first-page":"25579","DOI":"10.52965\/001c.25579","volume":"13","author":"J Kakazu","year":"2021","unstructured":"Kakazu J, Walker NL, Babin KC, Trettin KA, Lee C, Sutker PB, Kaye AM, Kaye AD (2021) Risdiplam for the use of spinal muscular atrophy. Orthop Rev 13:25579","journal-title":"Orthop Rev"},{"key":"3_CR66","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1091\/mbc.e13-01-0042","volume":"24","author":"DY Kwon","year":"2013","unstructured":"Kwon DY, Dimitriadi M, Terzic B, Cable C, Hart AC, Chitnis A, Fischbeck KH, Burnett BG (2013) The E3 ubiquitin ligase mind bomb 1 ubiquitinates and promotes the degradation of survival of motor neuron protein. Mol Biol Cell 24:1863\u20131871","journal-title":"Mol Biol Cell"},{"issue":"1","key":"3_CR67","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M et al (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80(1):155\u2013165","journal-title":"Cell"},{"issue":"16","key":"3_CR69","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.4155\/fmc.12.131","volume":"4","author":"MA Lorson","year":"2012","unstructured":"Lorson MA, Lorson CL (2012) SMN-inducing compounds for the treatment of spinal muscular atrophy. Future Med Chem 4(16):2067\u20132084","journal-title":"Future Med Chem"},{"issue":"9630","key":"3_CR70","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","volume":"371","author":"MR Lunn","year":"2008","unstructured":"Lunn MR, Wang CH (2008) Spinal muscular atrophy. Lancet 371(9630):2120\u20132133","journal-title":"Lancet"},{"issue":"6","key":"3_CR79","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.neuron.2005.12.001","volume":"48","author":"UR Monani","year":"2005","unstructured":"Monani UR (2005) Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron-specific disease. Neuron 48(6):885\u2013896","journal-title":"Neuron"},{"key":"3_CR80","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.8493530","volume":"260","author":"RC Mulligan","year":"1993","unstructured":"Mulligan RC (1993) The basic science of gene therapy. Science 260:926\u2013932","journal-title":"Science"},{"key":"3_CR87","volume":"15","author":"T Ogbonmide","year":"2023","unstructured":"Ogbonmide T, Rathore R, Rangrej SB, Hutchinson S, Lewis M, Ojilere S, Carvalho V, Kelly I (2023) Gene therapy for spinal muscular atrophy (SMA): a review of current challenges and safety considerations for onasemnogene abeparvovec (Zolgensma). Cureus 15:e36197","journal-title":"Cureus"},{"issue":"12","key":"3_CR91","first-page":"1300","volume":"25","author":"SD Pearson","year":"2019","unstructured":"Pearson SD, Thokala P, Stevenson M, Rind D (2019) The effectiveness and value of treatments for spinal muscular atrophy. J Manag Care Spec Pharm 25(12):1300\u20131306","journal-title":"J Manag Care Spec Pharm"},{"issue":"8","key":"3_CR97","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/hmg\/ddq023","volume":"19","author":"M Riessland","year":"2010","unstructured":"Riessland M, Ackermann B, Forster A, Jakubik M, Hauke J, Garbes L, Fritzsche I, Mende Y, Blumcke I, Hahnen E, Wirth B (2010) SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum Mol Genet 19(8):1492\u20131506","journal-title":"Hum Mol Genet"},{"issue":"3","key":"3_CR99","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s004390100473","volume":"108","author":"CF Rochette","year":"2001","unstructured":"Rochette CF, Gilbert N, Simard LR (2001) SMN gene duplication and the emergence of the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiens. Hum Genet 108(3):255\u2013266","journal-title":"Hum Genet"},{"issue":"124","key":"3_CR109","first-page":"1","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Wilson IJ et al (2017) Prevalence, incidence and carrier frequency of 5q\u2013linked spinal muscular atrophy \u2013 a literature review. Orphanet J Rare Dis 12(124):1\u201315","journal-title":"Orphanet J Rare Dis"},{"key":"3_CR111","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.201800268","volume":"2","author":"Y Wang","year":"2019","unstructured":"Wang Y, Xu C, Ma L, Mou Y, Zhang B, Zhou S et al (2019) Drug screening with human SMN2 reporter identifies SMN protein stabilizers to correct SMA pathology. Life Sci Alliance 2:e201800268","journal-title":"Life Sci Alliance"}],"container-title":["Advances in Experimental Medicine and Biology","Petri Nets in Systems Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-032-20041-9_3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T23:03:13Z","timestamp":1779663793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-032-20041-9_3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9783032200402","9783032200419"],"references-count":28,"URL":"https:\/\/doi.org\/10.1007\/978-3-032-20041-9_3","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"25 May 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}